IGC Pharma Inc banner

Intrinsic Value

Not Available for IGS1

There is not enough data to reliably calculate the intrinsic value for IGC Pharma Inc.

Do our valuations actually work? See backtest results .

Alternatives to IGS1

Fundamental Analysis

What IGC Pharma Does

Pharmaceuticals Health Care

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The firm's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions.

Headquarters
United States of America US
Employees
70
IPO date
Apr 13, 2006
Read the full company overview
View Company Overview
Financials
Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Continue IGS1 Research

Decided on IGC Pharma? Get an email when IGS1 reaches the price you’d buy at. Free with an account.

Other IGC Pharma listings

Back to Top